P2Y2R and Cyst Growth in Polycystic Kidney Disease
- PMID: 38848134
- PMCID: PMC11452133
- DOI: 10.1681/ASN.0000000000000416
P2Y2R and Cyst Growth in Polycystic Kidney Disease
Abstract
Key Points:
Polycystic kidney disease (PKD) is characterized by continuous cyst growth, which results in a decline in kidney function.
Deletion of P2Y2R and pharmacological antagonism of purinergic signaling significantly reduced cyst growth in an orthologous PKD mouse model.
P2Y2R was expressed in cysts of human PKD nephrectomies, which makes P2Y2R a reasonable target for treatment of PKD.
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by multiple bilateral kidney cysts that gradually enlarge, resulting in a decline in kidney function. Cyst growth is significantly driven by ATP-dependent chloride secretion mediated by the ion channel TMEM16A. This pathway is further augmented in advanced stages of the disease by hypoxia and activation of hypoxia-inducible factor (HIF)-1α. The mechanisms by which ATP leads to activation of TMEM16A and how HIF-1α contributes to cyst growth in vivo have remained elusive.
Methods: Mice with an inducible tubule-specific deletion of Pkd1 were compared with mice with an additional codeletion of the purinergic receptor P2y2r. Furthermore, animals were challenged by pharmacological activation of HIF-1α and Pkd1-deficient mice were treated with suramin, an antagonist of purinergic signaling. In addition, expression of P2Y2R, TMEM16A, and HIF-1α was analyzed in nephrectomy samples from 27 patients with ADPKD.
Results: Genetic deletion of P2y2r significantly inhibited cyst growth in vivo. In addition, aggravation of the polycystic phenotype mediated by pharmacological activation of HIF-1α was reduced by deletion of P2y2r. Application of suramin to pharmacologically inhibit purinergic signaling also suppressed cyst enlargement in vivo. Analysis of kidney samples from 27 patients with ADPKD revealed significant expression of P2Y2R at the luminal site of the cyst-lining epithelium.
Conclusions: P2Y2R was significantly expressed in human and mouse polycystic kidneys. Deletion and antagonism of P2Y2R reduced cyst enlargement in an ADPKD mouse model.
Conflict of interest statement
Disclosure forms, as provided by each author, are available with the online version of the article at
Similar articles
-
Coexistence of autosomal dominant polycystic kidney disease type 1 and hereditary renal hypouricemia type 2: A model of early-onset and fast cyst progression.Clin Genet. 2020 Jun;97(6):857-868. doi: 10.1111/cge.13738. Epub 2020 Mar 25. Clin Genet. 2020. PMID: 32166738
-
The impact of maternal obesity on polycystic kidney disease progression in a mouse model.Am J Physiol Renal Physiol. 2025 Mar 1;328(3):F316-F327. doi: 10.1152/ajprenal.00227.2024. Epub 2025 Feb 5. Am J Physiol Renal Physiol. 2025. PMID: 39908005 Free PMC article.
-
Polycystic kidney disease: the complexity of planar cell polarity and signaling during tissue regeneration and cyst formation.Biochim Biophys Acta. 2011 Oct;1812(10):1249-55. doi: 10.1016/j.bbadis.2011.05.005. Epub 2011 May 27. Biochim Biophys Acta. 2011. PMID: 21640821 Review.
-
Kidney stone formation in a novel murine model of polycystic kidney disease.Am J Physiol Renal Physiol. 2022 Jul 1;323(1):F59-F68. doi: 10.1152/ajprenal.00165.2021. Epub 2022 Mar 28. Am J Physiol Renal Physiol. 2022. PMID: 35343849 Free PMC article.
-
Kidney organoid models of polycystic kidney disease: challenges and future directions.Am J Physiol Renal Physiol. 2025 Jul 1;329(1):F143-F159. doi: 10.1152/ajprenal.00116.2025. Epub 2025 Jun 11. Am J Physiol Renal Physiol. 2025. PMID: 40499561 Review.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources